Supernus Pharmaceuticals, Q2 2026 Earnings Call Transcript

Supernus and Indivior plan an all-stock merger of equals, creating a CNS-focused company with 11 marketed medicines across addiction, ADHD, depression and Parkinson’s disease. The companies project about $2.2 billion in annual net revenue and $888 million in adjusted EBITDA, including $125 million in annual cost synergies expected within the first 12 months after closing. They expect the deal to close in the fourth quarter of 2026, subject to shareholder and regulatory approvals.

Management expects the combined company’s growth products to support expansion well into the 2030s and says greater financial flexibility will enable continued investment in its portfolio, pipeline and business development. Indivior sees a durable growth runway for SUBLOCADE, citing record new patient starts, market share stable at 76% and low long-acting injectable penetration; it points to manufacturing complexity and existing patents extending from 2031 to 2038, while pursuing additional protection. The companies describe potential competitive developments in opioid use disorder and ADHD as early-stage.